Comments

Share via

WV CAG joined other consumer protection and health care advocacy organizations in signing a letter of support for the administrative appeal of a request for the Department of Health and Human Services (HHS) to use its rights in the federally-funded patented inventions for the prostate cancer drug enzalutamide (brand name Xtandi), in order to address a failure by the current licensed patent holders. Astellas and Pfizer have failed to make the drug “available to the public on reasonable terms.” As a result, cancer patients and everyone else who pays for drug reimbursements, are subject to highly objectionable discriminatory price gouging. The letter calls on the Biden Administration to remedy the outrageous price discrimination against US residents by Astellas and provide relief from the high prices.

More about the letter and the Xtandi appeal here.